<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Bramble: Peptide drugs</title>
    <link>https://news.ketelle.co.uk/entities/peptide-drugs</link>
    <description>Stories involving Peptide drugs, told neutrally, with how each side covers them.</description>
    <language>en-gb</language>
    <atom:link href="https://news.ketelle.co.uk/entities/peptide-drugs/feed.xml" rel="self" type="application/rss+xml"/>
    <item>
      <title>HHS sends peptide "interim access policy" for compounding pharmacies to White House review</title>
      <link>https://news.ketelle.co.uk/stories/trump-administration-advances-plan-letting-pharmacies-compound-peptide</link>
      <guid isPermaLink="true">https://news.ketelle.co.uk/stories/trump-administration-advances-plan-letting-pharmacies-compound-peptide</guid>
      <pubDate>Fri, 16 Oct 2026 20:10:37 +0100</pubDate>
      <category>Health</category>
      <description>A proposed "interim access policy" on peptide drugs has gone to the White House for review. According to anonymous sources cited by AP, it would let compounding pharmacies make some popular peptides without FDA enforcement. FDA staff scientists say the drugs are unproven. (2 outlets: 1 left · 1 centre · 0 right)</description>
      <media:content url="https://www.statnews.com/wp-content/uploads/2026/08/AP26215050550263-1024x576.jpg" medium="image"/>
    </item>
  </channel>
</rss>
